mTOR vs AMPK: Why MOTS-C Can Kill Your Muscle Gains

Timing MOTS-C Around Your Training: The mTOR and AMPK Question

Nobody has actually measured that in a human, but if I was to kind of explain the concept of mTOR versus AMPK, it's basically this, okay? When I go into the gym and I lift heavy weights and I put myself to a point where I'm lifting to failure with resistance training, bench press, squats, deadlifts, et cetera, what happens is that anaerobic activity signals something called mTOR. And mTOR is your cell signal to turn on muscle protein synthesis, build more muscle. I cannot point you to a study that measured that exact signaling chain in a trained human after a heavy set, so treat this as the model I work from and not as settled fact.

The whole question only makes sense once you see the decision your cells are making.

Building new muscle protein is expensive, so a cell will only do it when fuel is plentiful and there is a mechanical reason to grow. Burning fuel efficiently and building more mitochondria is the opposite move, and a cell does that when energy is scarce and demand is long and steady. mTOR sits on the building side. Something called AMPK sits on the other side, and it is the sensor that reads low cellular energy and shifts the cell toward producing fuel rather than spending it on growth.

Now, one thing that's interesting about the mTOR versus AMPK signals is the fact that they're competing, meaning I can't have them both active at the same time. The research hasn't given us a clean human study showing those two switches locking each other out in skeletal muscle after real training, so this is the mechanistic picture I use and not something proven in lifters.

Think of a house with one electrical panel, where the heavy construction equipment and the backup generator draw off the same circuit, and flipping one on pulls current away from the other.

So drugs like the SLUPP family, peptides like MOTC, they activate AMPK, which is that endurance signal. The AMPK part is the piece with real data behind it.

MOTS-c is a peptide your mitochondria encode, and in the original characterization work it activated AMPK and pushed cells toward using glucose more aggressively, with treated mice resisting diet-induced obesity and insulin resistance on a high fat diet (Lee 2015). A later study traced the same peptide driving glycolysis through an AMPK dependent pathway in lung tissue, which tells you the AMPK arm is not a one-off finding (Shen 2025).

That is the whole reason timing comes up. If MOTS-c reliably pushes AMPK, and AMPK and mTOR compete for the same cell, then dosing an hour before your heaviest pressing session is asking that cell to run a growth program and a fuel-conservation program in the same window.

Theoretically and from a mechanistic standpoint, the answer is yes, right? But again, this isn't something that it's been directly studied in humans.

The fix costs you nothing. But if you're specifically in a, we'll say bulking or building phase, try to remove the MOTC from those lifting days and put it directly with the cardio that you're doing, similar to the way that I just described.

If cardio and lifting land on the same day, separate them by as many hours as you can and dose next to the cardio.

In a fat loss phase the calculus flips, because you are not protecting a growth signal so much as holding onto tissue while burning fuel, and the AMPK push is closer to what you want anyway.

None of this changes what the peptide does. It changes when you let it speak, and a signal that helps you at four in the afternoon can work against you at ten in the morning.

Research: Lee 2015, Cell Metab; Shen 2025, Am J Respir Cell Mol Biol.

References:

Lee C, Zeng J, Drew BG et al.. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015. https://pubmed.ncbi.nlm.nih.gov/25738459/

Shen Z, Lu P, Jin W et al.. MOTS-c Promotes Glycolysis via AMPK-HIF-1α-PFKFB3 Pathway to Ameliorate Cardiopulmonary Bypass-induced Lung Injury. Am J Respir Cell Mol Biol. 2025. https://pubmed.ncbi.nlm.nih.gov/40035775/